BLUE
Closed
Bluebird Bio Inc
4.97
0.00 (0.00%)
Last Update: 02 Jun 2025 16:30:00
Yesterday: 4.97
Day's Range: 4.97 - 4.97
Send
sign up or login to leave a comment!
When Written:
3.18
Bluebird bio Inc is a biotechnology company that focuses on developing gene therapies for severe genetic diseases and cancer. The company was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Bluebird bio's gene therapies are designed to replace or repair defective genes in a patient's cells. The company's lead product candidate, Zynteglo, is a gene therapy for beta-thalassemia, a rare blood disorder. Bluebird bio is also developing gene therapies for sickle cell disease, cerebral adrenoleukodystrophy, and multiple myeloma.
Bluebird bio has partnerships with several pharmaceutical companies, including Bristol-Myers Squibb and Regeneron, to develop and commercialize gene therapies.
The company has received several awards and recognitions for its work in gene therapy, including being named one of the World's Most Innovative Companies by Fast Company in 2019.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Bluebird bio's gene therapies are designed to replace or repair defective genes in a patient's cells. The company's lead product candidate, Zynteglo, is a gene therapy for beta-thalassemia, a rare blood disorder. Bluebird bio is also developing gene therapies for sickle cell disease, cerebral adrenoleukodystrophy, and multiple myeloma.
Bluebird bio has partnerships with several pharmaceutical companies, including Bristol-Myers Squibb and Regeneron, to develop and commercialize gene therapies.
The company has received several awards and recognitions for its work in gene therapy, including being named one of the World's Most Innovative Companies by Fast Company in 2019.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








